#1
|
||||
|
||||
Тератогенное воздействие мифепристона
Уважаемые коллеги! В свете применения средств экстренной контрацепции, интересует вопрос о тератогенном воздействии мифепристона. Нашел лишь старые и противоречивые данные (например,один из источников: [Ссылки доступны только зарегистрированным пользователям ] 29 стр). Хотел бы внести по возможности ясность в этот вопрос. Может, кто-то подскажет или поделится ссылками?
|
#2
|
||||
|
||||
вот такие рекомендации: [Ссылки доступны только зарегистрированным пользователям ]
__________________
Искренне, Вадим Валерьевич. |
#3
|
||||
|
||||
вот такое с этой статьи:
7.2.1.3. Ongoing pregnancies. After more than 10 years of mifepristone use in several European countries, a few case reports of normal pregnancies and offspring have been recorded when women have taken mifepristone alone or in combination with a prostaglandin; these women had not aborted and had elected to continue their pregnancies [51]. Only one anomaly was reported after the use of mifepristone alone. This case, described as sirenomelia [52], could not be related to the drug intake. Indeed, the type of anomaly observed occurred at a very early stage of pregnancy, about 4 weeks of embryo development, while the treatment was taken at the 5th week of pregnancy. Seven other cases of malformations were reported, and all occurred in pregnancies of 7–9 weeks of amenorrhea and when gemeprost was administered after mifepristone. None of the described events could be related to the combination of treatment. Given the known incidence of birth defects in a normal population, around 2.5% per year in the European registry, it is not possible to determine whether the reported anomalies were coincidental or not. Some prostaglandins have been classified as teratogenic, however, misoprostol did not induce such effects in embryotoxicology studies. Although mifepristone is not a teratogenic agent, its effect on uterine contractility, when used in combination with a prostaglandin, may induce uterine retraction accounting for some of the observed defects [12]. For other indications in which the drug is administered in much lower doses and not during embryo development, there is no reason to believe that such risk would exist. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies [Ссылки доступны только зарегистрированным пользователям ]
__________________
Искренне, Вадим Валерьевич. |
#4
|
||||
|
||||
Спасибо, коллега, ценная информация!
|